Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question.

Literature DB >> 27892994

Adoption of Pathologic Complete Response as a Surrogate End Point in Neoadjuvant Trials in HER2-Positive Breast Cancer Still an Open Question.

Tomasz Burzykowski¹, Everardo D Saad², Marc Buyse³.

Abstract

Entities: Disease

Mesh：

Substances：
Receptor, ErbB-2

Year: 2017 PMID： 27892994 DOI： 10.1001/jamaoncol.2016.3941

Source DB: PubMed Journal: JAMA Oncol ISSN： 2374-2437 Impact factor: 31.777

Keyword Cloud
Cited

× No keyword cloud information.

1 in total

1. Disease-free survival as a surrogate for overall survival in patients with HER2-positive, early breast cancer in trials of adjuvant trastuzumab for up to 1 year: a systematic review and meta-analysis.

Authors: Everardo D Saad; Pierre Squifflet; Tomasz Burzykowski; Emmanuel Quinaux; Suzette Delaloge; Dimitris Mavroudis; Edith Perez; Martine Piccart-Gebhart; Bryan P Schneider; Dennis Slamon; Norman Wolmark; Marc Buyse
Journal: Lancet Oncol Date: 2019-01-29 Impact factor: 41.316

1 in total